UPC Analytics
ENDE
Analytics1Cases1Decisions4Judges3Parties2Firms
Filing trendsOutcomesPendencyTechnologyForum strategyLeading casesLegal issuesSecurity for costs

Outcome base rates

What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.

Legal principleR. 295 RoP stay of proceedings does not apply to PI proceedingsClear all
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.

No merits decisions in the current scope.

PI grant rate
0%
0 granted · 1 denied · 1 total decisions
PI grant rate (conservative)
0%
Granted / total PI decisions (incl. interim, withdrawn)
Infringement rate
—
Revocation rate
—
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 1
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
  • Provisional measures1
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
  • Dusseldorf LD1 casesPI grant rate: 0%Infringement rate: —Revocation rate: —
Recent decisions
Most recent decisions in scope.
  • 2024-09-06ACT_18551/2024PI deniedOrder by Düsseldorf Local Division (UPC_CFI_166/2024, 6 September 2024) rejecting Novartis AG and Genentech Inc.'s application for provisional measures against Celltrion Inc. for alleged infringement of EP 3 805 248 B1 (biologic/antibody). The application was dismissed on the merits (infringement insufficiently established). Applicants were ordered to pay interim costs of EUR 138,562.80. The court addressed claim interpretation, imminent infringement, non-applicability of stay of proceedings (R. 295 RoP) to PI proceedings, and the costs gap in the absence of main proceedings.